skyrocket

Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook by $2 billion, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro spiked again. The pharmaceutical giant now expects 2026 revenue to come in between $82 billion and $85 billion, up from…